Abstract
The investigational anti-complement component 5a (C5a) antibody vilobelimab (Gohibic - InflaRx) has been granted an FDA Emergency Use Authorization (E......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
